Table 5.
Pericardial sclerosis for the management of malignant pericardial effusion in patients with lung cancer [8,9,10,11].
| Agent | Dose Administered | Patient Number | Histology (NSCLC/SCLC a) | Number of Cases Successfully Controlled/Total Number of Patients (%) |
Adverse Events | Median Survival (Days) | References |
|---|---|---|---|---|---|---|---|
| Carboplatin | 300 mg/body | 10 | 10/0 | 8/10 (80%) | None | 69 | Moriya et al. (2000) [11] |
| Mitomycin C | 2 mg/body | 8 | 8/0 | 6/8 (75%) | None | 80 | Kaira et al. (2005) [10] |
| Bleomycin | 10 mg/body | 22 | 22/0 | 21/22 (95%) | Anemia (n = 2), Hypoalbuminemia (n = 3), Liver dysfunction (n = 3), Hyponatremia (n = 2), Fever (n = 6), Sinus tachycardia (n = 2), Leukopenia (n = 2) | 125 | Maruyama et al. (2007) [9] |
| Bleomycin | 15 mg/body | 38 | 36/2 | 25/38 (65%) | Fever (n = 2), Pain (n = 13), Infection (n = 3), Bleeding (n = 2), Cardiac dysfunction (n = 1), Constrictive pericarditis (n = 1) | 119 | Kunitoh et al. (2009) [8] |
| Carboplatin | 150 mg/body | 21 | 18/3 | 14/21 (67%) | Pain (n = 3), Nausea (n = 2), Fever (n = 2), Neutropenia (n = 2) | 71 | Current study |
a NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.